Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Click here to learn more about the CDC guidance to help prevent TBE.
what-is-tbe
Some ticks found across parts of Europe and Asia may be carriers of the Tick-Borne Encephalitis (TBE) virus, a rare virus that can lead to infection of the brain and spine, and, potentially, lead to serious lifelong health complications.1,2
  
And, there’s no cure for TBE.3

WHAT IS TBE?

are-you-at-risk
Are You at Risk?
Are you traveling to Asia or Europe? Know the where, when, and how of TBE virus to help keep yourself protected.4​​​​​​​

LEARN MORE​​​​​​​

prevention
Prevention
Following a few simple steps may help you protect yourself from being bitten by a tick.5,6

LEARN MORE​​​​​​​

vaccine
What is TicoVac™?
Vaccination is an effective prevention method for TBE.2 Learn how TicoVac™ can help protect travelers from TBE.

LEARN MORE​​​​​​​

find a ticovacfind a ticovac
Find TicoVac™ 
​​​​​​​
Near You
The best place to get international travel health information specific to you and your travel plans is to contact your healthcare provider or pharmacist.

FIND TICOVAC™

References
  1. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861-1871. doi:10.1016/S0140-6736(08)60800-4.
  2. Barrett PN, Portsmouth D, Ehrlich HJ. Tick-borne encephalitis virus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Elsevier Saunders; 2013:773-788.
  3. Dobler G, Erber W, Bröker M, Schmitt HJ, eds. The TBE Book. 4th ed. Global Health Press; 2021.
  4. Fischer M, Gould CV, Rollin PE. Tickborne Encephalitis. Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University Press; 2017. Chap 4. Accessed February 24, 2022. https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/tickborne-encephalitis.
  5. Travel Health Pro. Diseases in Brief. Tick-borne encephalitis. Accessed February 24, 2022. https://travelhealthpro.org.uk/disease/173/tick-borne-encephalitis.
  6. Travel Health Pro Factsheets. Insect and tick bite avoidance. Accessed February 24, 2022. https://travelhealthpro.org.uk/factsheet/38/insect-and-tick-bite-avoidance.

IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
  • TicoVac™ should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac™. 
  • TicoVac™ may not protect all individuals against TBE.
  • Some individuals with weakened immune systems may have a reduced immune response.
  • TicoVac™ contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
  • The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac™ were local tenderness, local pain, headache, fever, and restlessness.
  • The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac™ were local tenderness, local pain, fatigue, headache, and muscle pain.
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant.
  • Ask your healthcare provider about the risks and benefits for TicoVac™. Only a healthcare provider can decide if TicoVac™ is right for you.
Indication

TicoVac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
  • TicoVac™ should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac™. 
  • TicoVac™ may not protect all individuals against TBE.
  • Some individuals with weakened immune systems may have a reduced immune response.
  • TicoVac™ contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
  • The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac™ were local tenderness, local pain, headache, fever, and restlessness.
  • The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac™ were local tenderness, local pain, fatigue, headache, and muscle pain.
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant.
  • Ask your healthcare provider about the risks and benefits for TicoVac™. Only a healthcare provider can decide if TicoVac™ is right for you.
Indication

TicoVac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries.

The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

  • © 2022 Pfizer Inc.
  • All rights reserved.
  • Pfizer Inc. PO Box 29387, Mission, KS 66201
  • May 2022
  • PP-TCV-USA-0043
  • PP-TCV-USA-0043
  • PP-TCV-USA-0043